1 · Case at a Glance
§ SUMMARYBorn 17 Apr 2026 at 16:20 at 29 +0/7 weeks GA, birth weight 1310 g. Cried twice at delivery, but had recurrent apnea attributed to apnea of prematurity. Immediately intubated in the delivery room and transferred to NICU on a Hamilton-G5 ventilator in P-CMV mode.
The first venous blood gas at ~3 h of life demonstrated severe mixed acidosis: pH 7.022, pCO₂ 127.9 mmHg, HCO₃⁻ 33.2 mmol/L, on FiO₂ 40 %.
Empiric antibiotics were started on Day 1 (Penicillin G "Polypen" + Amikacin) and have since been escalated twice — first to Piperacillin-Tazobactam ("Vigocid") on Day 7, then to Meropenem ("Meromax") on Day 11.
Despite 18 days of mechanical ventilation and antibiotic escalation, the infant remains ventilator-dependent with persistent severe hypercapnia (last 5 ABGs: pCO₂ 90.8 → 105.4 → 111.1 → 102.1 → 100.6 mmHg). The 5 May gas shows pH 7.391 — apparently "normal", but only because HCO₃⁻ has climbed to 61.8 mmol/L (BE +36.6). This is well beyond the expected metabolic compensation for chronic respiratory acidosis (predicted HCO₃⁻ ≈ 45 for sustained pCO₂ ≈ 100), suggesting an additional metabolic alkalosis component — possible aetiologies include iatrogenic NaHCO₃, occult diuretic effect, NG / gastric losses, or contraction alkalosis. The "normal" pH is reassuring on its face but masks unchanged ventilatory failure.
Chest x-rays show a triphasic course: initial right paracardiac haziness (4/17), partial clearing (4/22), interval progression to bilateral hazy-streaky opacities (4/27), and now slight clearing again on the 5/02 follow-up. The 5/02 film also flagged the ETT tip at the carina — repositioning suggested.
The new 2D-echo with Doppler (5/04 06:59) rules out PDA but identifies pulmonary hypertension (PAP 48 mmHg) with otherwise normal LV function (LVEF 77 %) and a small, expected PFO. This reframes the underlying physiology of the refractory hypercapnia.
Blood culture drawn at admission was negative at 5 days. CRP normalised from 28.6 → 2.75 mg/L by Day 4. The most recent CBC (5/03) shows WBC 13.49, ANC 6.96, and a declining haemoglobin (17.2 → 16.4 → 10.7 g/dL) consistent with anaemia of prematurity / phlebotomy losses.
2 · Specific Clinical Concerns
§ CONCERNSFor a 29-week preterm with respiratory failure requiring intubation in the delivery room, exogenous surfactant (poractant alfa, beractant, or calfactant) is widely considered standard of care for established or impending respiratory distress syndrome (RDS). The 2022 European Consensus Guidelines on Management of RDS recommend early rescue surfactant for any preterm infant requiring intubation for RDS. No surfactant product appears in the itemized billing from 17 Apr through 26 Apr.
Methylxanthine therapy (caffeine citrate) is a Cochrane-supported, AAP-endorsed standard of care for preterm infants <32 weeks. It treats apnea of prematurity, has been shown to reduce the duration of mechanical ventilation and rates of bronchopulmonary dysplasia (CAP trial, NEJM 2006), and is typically initiated within the first 72 hours. Despite this infant's documented apnea of prematurity at delivery (the stated indication for intubation), no caffeine citrate / Cafcit / Peyona is documented in the billing record.
The 2D-Echo with Doppler was performed on 4 May 2026 at 06:59 by Dr. Francisco Emilio Remotigue Jr. (delayed until DOL 17 — i.e. after 16 days of refractory hypercapnia and a worsening CXR). Headline findings:
- No patent ductus arteriosus — hsPDA can be removed from the differential.
- Pulmonary arterial pressure (PAP) 48 mmHg by pulmonary acceleration time — well above the <25 mmHg normal threshold; this is pulmonary hypertension.
- Patent foramen ovale 0.10 cm — small, common in newborns, expected to close.
- Normal LV function: LVEF 77 %, FS 42 %; normal chamber sizes; no coarctation.
The PHTN finding is consistent with — and may be a primary driver of — the persistent hypercapnia and ventilator dependence. It is also a finding with specific therapeutic options that have not yet been deployed in this patient (see Differential and Suggested Investigations sections): inhaled nitric oxide (iNO), sildenafil, optimisation of oxygenation, and avoidance of acidosis (which itself raises PVR — and this patient's recent pH was 7.178).
Initial empiric coverage (Penicillin G + Amikacin) was reasonable. However:
- Blood culture drawn 17 Apr 19:47 returned no growth at 5 days (validated 23 Apr).
- CRP fell from 28.6 mg/L (18 Apr) to 2.75 mg/L (21 Apr) — within normal range.
- Despite this, antibiotics were escalated to Piperacillin-Tazobactam on 23 Apr and to Meropenem ("Meromax") on 27–28 Apr.
Reviewers should comment on whether continued antibiotic exposure is justified, what cultures (tracheal aspirate, repeat blood, urine) have been obtained, and whether a non-infectious cause for the worsening x-ray is being adequately evaluated.
The infant has remained on P-CMV (pressure control, time-cycled) for the entire 16-day course on the Hamilton G5. Modern neonatal ventilation typically favours a volume-targeted mode (e.g., PSV + Volume Guarantee, PRVC, or APV-CMV / APVsimv on the G5) which has Cochrane evidence for reduced rates of pneumothorax, BPD, severe IVH, and duration of ventilation. Tidal-volume monitoring shows substantial variability (Vte/kg ranging 7.3 – 15.7 mL/kg) — both volutrauma (high) and atelectotrauma (low) ranges are present. Reviewers may wish to comment on optimal mode selection.
The 27 Apr film described "interval progression of hazy and streaky opacities now involving both lung fields". A repeat CXR was finally obtained on 2 May 2026 (5 days later) and reads as "interval slight clearing of the hazy and streaky opacities in both lung fields" — modest improvement of the parenchymal pattern.
However the same 5/02 report flags a new mechanical concern: "the endotracheal tube is again seen with its tip at the level of the carina — repositioning suggested." An ETT tip at the carina (rather than 1–2 cm above) risks selective right-mainstem intubation, asymmetric ventilation / left-lung atelectasis, and chronic carinal irritation. This is a fixable contributor to the persistent hypercapnia and is independent of the underlying lung disease. Reviewers should ask whether the ETT was retracted after this 5/02 report. No CT and no tracheal aspirate culture has been documented to further clarify the parenchymal aetiology.
The 5 May 05:51 venous gas reads pH 7.391 — superficially reassuring after the 7.178 of two days earlier. But pCO₂ is essentially unchanged at 100.6 mmHg, while HCO₃⁻ has climbed from 38 → 47 → 61.8 mmol/L and BE from +10 → +19 → +36.6. For a sustained pCO₂ of ~100, expected metabolic compensation in chronic respiratory acidosis is HCO₃⁻ ≈ 45 mmol/L. 61.8 substantially exceeds the predicted ceiling — implying an additional, non-respiratory metabolic alkalosis.
Differential for the metabolic-alkalosis component: (a) iatrogenic sodium bicarbonate or other base administration (does not appear in current billing but would not always); (b) occult or recently introduced diuretic effect (not in billing); (c) gastric / NG losses (vomiting or NG suction); (d) contraction alkalosis from intravascular volume depletion; (e) hypochloraemia of any cause. Reviewers should request a recent basic metabolic panel (Na, K, Cl, urea, creatinine), urine chloride (saline-responsive vs saline-unresponsive alkalosis), and a fluid-balance review. Until the cause is identified, the apparent pH normalisation should not be taken as clinical improvement.
3 · Clinical Timeline
§ TIMELINE4 · Blood Gases — pH, pCO₂, HCO₃⁻, Base Excess
§ ABG / VBGHypercapnia (pCO₂ > 55–60 mmHg) reflects inadequate alveolar ventilation. In acute respiratory acidosis the kidneys have not had time to compensate, so the pH falls. Chronic respiratory acidosis is characterised by progressive renal HCO₃⁻ retention (≈ 0.35 mmol/L rise in HCO₃⁻ for every 1 mmHg sustained rise in pCO₂). This patient's HCO₃⁻ has climbed from 33 → 48.7 mmol/L and BE from +2.2 → +21.6 over 16 days — the textbook fingerprint of chronic CO₂ retention. The pH is therefore "near-normal" but the underlying ventilatory failure is persistent and worsening.
5 · Ventilator Settings & Monitored Values
§ HAMILTON G56 · Chest X-Ray Reports
§ RADIOLOGY17 Apr — 22 Apr: initial right paracardiac haze (retained fetal lung fluid), then partial clearing. 27 Apr (5 days later): interval progression now involving both lung fields. 2 May 2026 (5 days after that): "interval slight clearing of the hazy and streaky opacities in both lung fields." Same 5/02 report flags ETT tip at the level of the carina — repositioning suggested.
📄 View full radiologist reports (verbatim)
7 · Echocardiogram (4 May 2026, DOL 17)
§ ECHO- Pulmonary arterial pressure 48 mmHg by pulmonary acceleration time (PAT 70 ms) — well above the < 25 mmHg normal threshold. Pulmonary hypertension territory.
- No patent ductus arteriosus — hsPDA can be removed from the differential.
- Patent foramen ovale 0.10 cm — small, expected in a neonate, not haemodynamically significant.
- Normal LV systolic function: LVEF 77 %, FS 42 %; normal chamber sizes; intact IVS; no coarctation.
- All pulmonary veins drain to LA; situs solitus, levocardia; AV and VA concordance.
Clinical implication: the persistent hypercapnia and ventilator dependence are not driven by a left-to-right shunt. Pulmonary hypertension in a 29-week preterm at 31+3/7 wk PMA may be primary (PPHN, persistent fetal circulation) or secondary to chronic lung disease / chronic hypoxia / hypercapnia / acidosis. Acidosis itself raises pulmonary vascular resistance — and this patient's recent pH was 7.178. Treatment options that have not yet been deployed: inhaled nitric oxide (iNO), oral or IV sildenafil, optimisation of oxygenation, correction of acidosis.
| PAP (estimated) | 48 mmHg ↑ (norm <25) |
| PAT | 70 ms |
| LVEF (Simpson) | 77 % (normal >55) |
| FS (computed) | 42 % (normal >28) |
| Stroke volume | 4 mL |
| LVEDd / LVESd | 1.4 / 0.8 cm |
| PFO | 0.10 cm (small, expected) |
| PDA | Absent |
- Situs Solitus, Levocardia
- Inferior vena cava right of spine draining to right atrium
- All pulmonary veins drain to left atrium
- Patent Foramen Ovale measuring 0.10 cm
- Intact interventricular septum
- Normal chamber sizes
- Atrioventricular and ventriculoarterial concordance
- Nonthickened atrioventricular and semilunar valves
- Good left ventricular systolic function (LVEF 77 %, FS 42 %)
- Pulmonary arterial pressure 48 mmHg by pulmonary acceleration time
- Left sided aortic arch
- No Patent ductus arteriosus
- No coarctation of the aorta
8 · Other Laboratory Data
§ LABS9 · Medications & Respiratory-Relevant Items
§ PHARMACY10 · Procedures & Diagnostics Performed
§ PROCEDURES11 · Working Differential for Refractory Hypercapnia
§ DIFFERENTIAL1. Pulmonary hypertension (PHTN). Confirmed on 4 May echo: PAP 48 mmHg by PAT. May be primary (persistent fetal circulation / PPHN) or secondary to chronic hypoxia, hypercapnia, acidosis, and chronic lung disease — likely the latter in this clinical setting. PHTN raises right-ventricular afterload, can cause R-to-L shunt across the PFO, and impairs gas exchange. Specific therapeutic options: inhaled nitric oxide (iNO), oral or IV sildenafil, optimisation of oxygenation (SpO₂ > 92 %), correction of acidosis (avoid pH < 7.25), avoid hypothermia. None of these has been deployed.
2. Evolving Bronchopulmonary Dysplasia (BPD). Persistent oxygen requirement, ventilator dependence approaching 28 days of life, characteristic CXR progression. PMA at first definition of BPD is 36 weeks; this infant is currently 31 +3/7 wk PMA so this would be "evolving." BPD itself is a recognised cause of secondary PHTN.
3. Surfactant deficiency / RDS not adequately treated. No surfactant administered → would explain the very high initial pCO₂ (127.9) and persistently poor compliance. Late surfactant rescue is still considered if compliance remains poor.
4. ETT malposition. The 5/02 follow-up CXR reads ETT tip at the carina — repositioning suggested. Carinal positioning risks selective right-mainstem ventilation, atelectasis (typically left lung), and chronic carinal irritation. Easy to fix, easy to overlook.
5. Ventilator-associated pneumonia (VAP). Worsening bilateral CXR (now slightly improving on 5/02) despite negative initial blood culture. Tracheal aspirate culture has not been documented and would be informative.
6. Atelectasis / mucus plugging. P-CMV with variable Vte (7.3–15.7 mL/kg). Suctioning is documented but its effectiveness is not assessed in the available data.
7. Air-leak / pulmonary interstitial emphysema (PIE). Not seen on the available reports but a known complication of P-CMV without volume targeting. Lateral CXR recommended if progression recurs.
8. Central hypoventilation / drive issues. No sedative/opioid is listed in the visible billing, but the absence of caffeine (a respiratory stimulant) is a relevant negative.
9. Pulmonary haemorrhage. Would typically be more dramatic but worth ruling out via tracheal aspirate inspection.
10. PDA — now excluded. The 4 May echo confirms no patent ductus arteriosus. Removed from active differential.
- Echo done 4 May (PHTN, no PDA) — repeat in 5–7 days to assess response to therapy
- Repeat CXR after ETT repositioning
- Lung ultrasound
- Cranial ultrasound (last done 21 Apr — repeat at DOL ~28 for IVH/PVL)
- Tracheal aspirate culture & gram stain
- Repeat blood culture
- Urine culture
- Viral panel (RSV, influenza, etc.)
- Reticulocyte count, LDH, total/direct bilirubin (anaemia work-up)
- For PHTN: inhaled nitric oxide (iNO) trial; sildenafil; maintain SpO₂ > 92 %; correct acidosis
- ETT retraction per 5/02 CXR (tip at carina)
- Caffeine citrate loading dose + maintenance
- Late surfactant rescue (if compliance still poor)
- Switch to volume-targeted mode (e.g., APV-CMV with VT 4–5 mL/kg)
- pRBC transfusion (Hgb 10.7) + reduce phlebotomy losses
- HFOV trial if conventional fails